A previous evaluation of the T cell phenotype, by flow cytometry, in patients with stage IV melanoma or renal cell cancer treated with an anti-CTLA-4 reported an increased frequency of T cell subtypes such as CD4+, CD8+, CD4+CD25+, and CD4+CD25- that co-express the activation marker HLA-DR [119]. This evidence concerns the gene CD4 and renal cell adenocarcinoma.